Endocrine Abstracts

Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...